News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News Sweet Security Research Identifies Go Implementation of Node2Shell Vulnerability, Expanding Attack Surface to Major HTTP Frameworks News Savills Hong Kong Hosts Grand Reception to Celebrate 40th Anniversary News Micro-Dramas After 1 September 2026 – How China (Mainland) Rewrote the Rules News Hong Kong, Singapore, Tokyo: A Data Centre Comparison for Asian Site Selection News The Exhibition Hall of Achievements of China’s Language Resources Protection Project Officially Opens News HotelKey Announces Strategic Leadership Updates to Expand Global Footprint and Drive Operational Excellence
